GlassScriptPhysician profile
Fredda N Jackson
NPI 1487968012
$1,503.87
in general payments reported to CMS, 2019-2025
12 companies · $547 in 2025
The $547 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $27.77 · 2023: $345 · 2024: $419 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $527.76 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $235.60 | 2023-2025 | Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $201.33 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $197.36 | 2025 | Cobenfy |
| Abbvie INC. | $173.27 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $45.23 | 2024-2025 | Rexulti |
| Indivior INC. | $28.87 | 2022-2023 | Perseris |
| Lundbeck LLC | $26.55 | 2021 | |
| Almatica Pharma LLC | $21.96 | 2025 | Loreev Xr |
| Alkermes, INC. | $18.98 | 2025 | Lybalvi |
| Braeburn INC. | $13.63 | 2024 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredda Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.